Clinical Trials in Chicago

Showing 9521-9540 of 20,493 trials

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

NCT03041324

The purpose of the study is to evaluate the safety, tolerability and effect on leukocyte and plasma Iduronate 2-Sulfatase (IDS) enzyme activity of ascending doses of SB-913. SB-913 is an intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for genome editing. It inserts a correct copy of the IDS gene into the Albumin locus in hepatocytes with the goal of lifelong therapeutic production of the IDS enzyme.

Mucopolysaccharidosis IIMPS II

Sangamo Therapeutics9 participantsStarted May 2017

Oakland, California, United States • Chicago, Illinois, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 22.2 miles

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

NCT01767194

This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more effective in treating neuroblastoma.

GanglioneuroblastomaRecurrent Neuroblastoma

National Cancer Institute (NCI)73 participantsStarted Feb 2013

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Little Rock, Arkansas, United States +154 more locations

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Find Trials by Condition in Chicago

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV

Coordinated Oral Health Promotion (CO-OP) Chicago

Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement

Clinical Performance of Two Daily Disposable Toric Soft Contact Lenses

The Smart Pump Study

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

Primary Tube Versus Trabeculectomy Study

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

Study of Dapivirine Vaginal Ring (VR) in Adolescents

Engaging Moms on Teen Indoor Tanning Through Social Media

Therapy for Pediatric Hodgkin Lymphoma

A Study of LY2140023 in Patients With Schizophrenia

Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH